Short-course carbon-ion radiotherapy for hepatocellular carcinoma: A multi-institutional retrospective study

The Japan Carbon Ion Radiotherapy Study Group

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background & Aims: Carbon-ion radiation therapy has shown encouraging results in hepatocellular carcinoma patients in single-centre studies. We evaluated the effectiveness and safety of short-course carbon-ion radiation therapy for hepatocellular carcinoma in a multicentre study conducted by the Japan Carbon Ion Radiation Oncology Study Group. Methods: Consecutive hepatocellular carcinoma patients who were treated with carbon-ion radiation therapy in four or fewer fractions at four Japanese institutions between April 2005 and November 2014 were analysed retrospectively. The primary outcome was overall survival; secondary outcomes were local control rate, treatment-related toxicity and radiation-induced liver disease. Results: A total of 174 patients were included in this study. Prescribed carbon-ion radiation therapy doses were (relative biological effectiveness): 48.0 Gy in two fractions (n = 46), and 52.8 Gy (n = 108) and 60.0 Gy (n = 20) in four fractions. The median follow-up period was 20.3 (range, 2.9-103.5) months. The overall survival and local control rates at 1, 2 and 3 years were 95.4%, 82.5% and 73.3%; and 94.6%, 87.7% and 81.0% respectively. Multivariate analysis revealed that Eastern Cooperative Oncology Group performance status 1-2, Child-Pugh class B, maximum tumour diameter ≥3 cm, multiple tumours and serum alpha foetoprotein level >50 ng/mL were significant prognostic factors of overall survival. No treatment-related death occurred during the follow-up period. Grades 3 or 4 treatment-related toxicities were observed in 10 patients (5.7%); radiation-induced liver disease was observed in three patients (1.7%). Conclusions: Short-course carbon-ion radiation therapy is a safe, effective and potentially curative therapy for hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)2239-2247
Number of pages9
JournalLiver International
Volume38
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Heavy Ion Radiotherapy
Relative Biological Effectiveness
Hepatocellular Carcinoma
Retrospective Studies
Survival
Liver Diseases
Radiation
Radiation Oncology
alpha-Fetoproteins
Therapeutics
Multicenter Studies
Neoplasms
Japan
Carbon
Multivariate Analysis
Ions
Safety

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Short-course carbon-ion radiotherapy for hepatocellular carcinoma : A multi-institutional retrospective study. / The Japan Carbon Ion Radiotherapy Study Group.

In: Liver International, Vol. 38, No. 12, 01.12.2018, p. 2239-2247.

Research output: Contribution to journalArticle

The Japan Carbon Ion Radiotherapy Study Group. / Short-course carbon-ion radiotherapy for hepatocellular carcinoma : A multi-institutional retrospective study. In: Liver International. 2018 ; Vol. 38, No. 12. pp. 2239-2247.
@article{a15fe49ffe56433fabb19087de7681ca,
title = "Short-course carbon-ion radiotherapy for hepatocellular carcinoma: A multi-institutional retrospective study",
abstract = "Background & Aims: Carbon-ion radiation therapy has shown encouraging results in hepatocellular carcinoma patients in single-centre studies. We evaluated the effectiveness and safety of short-course carbon-ion radiation therapy for hepatocellular carcinoma in a multicentre study conducted by the Japan Carbon Ion Radiation Oncology Study Group. Methods: Consecutive hepatocellular carcinoma patients who were treated with carbon-ion radiation therapy in four or fewer fractions at four Japanese institutions between April 2005 and November 2014 were analysed retrospectively. The primary outcome was overall survival; secondary outcomes were local control rate, treatment-related toxicity and radiation-induced liver disease. Results: A total of 174 patients were included in this study. Prescribed carbon-ion radiation therapy doses were (relative biological effectiveness): 48.0 Gy in two fractions (n = 46), and 52.8 Gy (n = 108) and 60.0 Gy (n = 20) in four fractions. The median follow-up period was 20.3 (range, 2.9-103.5) months. The overall survival and local control rates at 1, 2 and 3 years were 95.4{\%}, 82.5{\%} and 73.3{\%}; and 94.6{\%}, 87.7{\%} and 81.0{\%} respectively. Multivariate analysis revealed that Eastern Cooperative Oncology Group performance status 1-2, Child-Pugh class B, maximum tumour diameter ≥3 cm, multiple tumours and serum alpha foetoprotein level >50 ng/mL were significant prognostic factors of overall survival. No treatment-related death occurred during the follow-up period. Grades 3 or 4 treatment-related toxicities were observed in 10 patients (5.7{\%}); radiation-induced liver disease was observed in three patients (1.7{\%}). Conclusions: Short-course carbon-ion radiation therapy is a safe, effective and potentially curative therapy for hepatocellular carcinoma.",
author = "{The Japan Carbon Ion Radiotherapy Study Group} and Kei Shibuya and Tatsuya Ohno and Kazuki Terashima and Shingo Toyama and Shigeo Yasuda and Hiroshi Tsuji and Tomoaki Okimoto and Yoshiyuki Shioyama and Kenji Nemoto and Tadashi Kamada and Takashi Nakano",
year = "2018",
month = "12",
day = "1",
doi = "10.1111/liv.13969",
language = "English",
volume = "38",
pages = "2239--2247",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Short-course carbon-ion radiotherapy for hepatocellular carcinoma

T2 - A multi-institutional retrospective study

AU - The Japan Carbon Ion Radiotherapy Study Group

AU - Shibuya, Kei

AU - Ohno, Tatsuya

AU - Terashima, Kazuki

AU - Toyama, Shingo

AU - Yasuda, Shigeo

AU - Tsuji, Hiroshi

AU - Okimoto, Tomoaki

AU - Shioyama, Yoshiyuki

AU - Nemoto, Kenji

AU - Kamada, Tadashi

AU - Nakano, Takashi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background & Aims: Carbon-ion radiation therapy has shown encouraging results in hepatocellular carcinoma patients in single-centre studies. We evaluated the effectiveness and safety of short-course carbon-ion radiation therapy for hepatocellular carcinoma in a multicentre study conducted by the Japan Carbon Ion Radiation Oncology Study Group. Methods: Consecutive hepatocellular carcinoma patients who were treated with carbon-ion radiation therapy in four or fewer fractions at four Japanese institutions between April 2005 and November 2014 were analysed retrospectively. The primary outcome was overall survival; secondary outcomes were local control rate, treatment-related toxicity and radiation-induced liver disease. Results: A total of 174 patients were included in this study. Prescribed carbon-ion radiation therapy doses were (relative biological effectiveness): 48.0 Gy in two fractions (n = 46), and 52.8 Gy (n = 108) and 60.0 Gy (n = 20) in four fractions. The median follow-up period was 20.3 (range, 2.9-103.5) months. The overall survival and local control rates at 1, 2 and 3 years were 95.4%, 82.5% and 73.3%; and 94.6%, 87.7% and 81.0% respectively. Multivariate analysis revealed that Eastern Cooperative Oncology Group performance status 1-2, Child-Pugh class B, maximum tumour diameter ≥3 cm, multiple tumours and serum alpha foetoprotein level >50 ng/mL were significant prognostic factors of overall survival. No treatment-related death occurred during the follow-up period. Grades 3 or 4 treatment-related toxicities were observed in 10 patients (5.7%); radiation-induced liver disease was observed in three patients (1.7%). Conclusions: Short-course carbon-ion radiation therapy is a safe, effective and potentially curative therapy for hepatocellular carcinoma.

AB - Background & Aims: Carbon-ion radiation therapy has shown encouraging results in hepatocellular carcinoma patients in single-centre studies. We evaluated the effectiveness and safety of short-course carbon-ion radiation therapy for hepatocellular carcinoma in a multicentre study conducted by the Japan Carbon Ion Radiation Oncology Study Group. Methods: Consecutive hepatocellular carcinoma patients who were treated with carbon-ion radiation therapy in four or fewer fractions at four Japanese institutions between April 2005 and November 2014 were analysed retrospectively. The primary outcome was overall survival; secondary outcomes were local control rate, treatment-related toxicity and radiation-induced liver disease. Results: A total of 174 patients were included in this study. Prescribed carbon-ion radiation therapy doses were (relative biological effectiveness): 48.0 Gy in two fractions (n = 46), and 52.8 Gy (n = 108) and 60.0 Gy (n = 20) in four fractions. The median follow-up period was 20.3 (range, 2.9-103.5) months. The overall survival and local control rates at 1, 2 and 3 years were 95.4%, 82.5% and 73.3%; and 94.6%, 87.7% and 81.0% respectively. Multivariate analysis revealed that Eastern Cooperative Oncology Group performance status 1-2, Child-Pugh class B, maximum tumour diameter ≥3 cm, multiple tumours and serum alpha foetoprotein level >50 ng/mL were significant prognostic factors of overall survival. No treatment-related death occurred during the follow-up period. Grades 3 or 4 treatment-related toxicities were observed in 10 patients (5.7%); radiation-induced liver disease was observed in three patients (1.7%). Conclusions: Short-course carbon-ion radiation therapy is a safe, effective and potentially curative therapy for hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85055153289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055153289&partnerID=8YFLogxK

U2 - 10.1111/liv.13969

DO - 10.1111/liv.13969

M3 - Article

C2 - 30240527

AN - SCOPUS:85055153289

VL - 38

SP - 2239

EP - 2247

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 12

ER -